Summary
- Dompé U.S. Inc. has agreed to pay $32 million to resolve allegations of violating the Anti-Kickback Statute and the False Claims Act by paying Medicare co-pays to induce purchases of its drug, Oxervate, from 2018 to 2021.
- The settlement follows Dompé's self-disclosure of its conduct, which involved contributions to patient assistance foundations that covered co-pays for Oxervate.
- U.S. Attorney Leah B. Foley emphasized that such kickbacks undermine Medicare and inflate drug costs, with her office recovering over $1.4 billion in similar cases.
- This case highlights the government's commitment to combating healthcare fraud and the importance of the False Claims Act in holding pharmaceutical companies
Join the discussion — sign up to comment, upvote, and save articles.